Advertisement

Clinical Rheumatology

, Volume 38, Issue 11, pp 3211–3215 | Cite as

The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014

  • Elham Rajaei
  • Nahid Shahbazian
  • Hadi Rezaeeyan
  • Amal Kia Mohammadi
  • Saeed Hesam
  • Zeinab Deris ZayeriEmail author
Original Article

Abstract

Background and aims

Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.

Material and methods

This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.

Result

The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (P value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (P value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The P value of cyclosporine was 0.0001 and the P value of methotrexate was 0.001.

Conclusion

Anti-phospholipid syndrome in women with SLE who intend to become pregnant can disrupt the development of the embryo. The consumption of methotrexate and cyclosporine medications before and during the pregnancy can have irreparable effects on fetal growth.

Key Points

Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant.

Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth.

7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy.

Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health.

Keywords

Anti-phospholipid syndrome Cyclosporine Fetus complications Methotrexate Pregnancy Systemic lupus erythematous 

Notes

Authors’ contributions

All authors contributed equally to this work.

Funding information

This study was supported by the Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Compliance with ethical standards

Disclosures

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Mowla K, Rajaei E, Jalali MT, Zayeri ZD (2018) Threatening biomarkers in lupus pregnancy: biochemistry and genetic challenges. Front Biol:1–8Google Scholar
  2. 2.
    Petri M (1994) Systemic lupus erythematosus and pregnancy. Rheum Dis Clin N Am 20(1):87–118Google Scholar
  3. 3.
    Tincani A, Bompane D, Danieli E, Doria A (2006) Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome). Lupus 15(3):156–160CrossRefGoogle Scholar
  4. 4.
    Dhar JP, Sokol RJ (2006) Lupus and pregnancy: complex yet manageable. Clin Med Res 4(4):310–321CrossRefGoogle Scholar
  5. 5.
    Witter FR (2007) Management of the high-risk lupus pregnant patient. Rheum Dis Clin N Am 33(2):253–265CrossRefGoogle Scholar
  6. 6.
    Ruiz-Irastorza G, Khamashta MA (2011) Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Investig 41(6):672–678CrossRefGoogle Scholar
  7. 7.
    Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts: part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123(1):42–53CrossRefGoogle Scholar
  8. 8.
    Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R (2016) Treatment with immunosuppressive and biologic drugs of pregnant women with systemic rheumatic or autoimmune disease. Medicina Clínica (English Edition) 147(8):352–360CrossRefGoogle Scholar
  9. 9.
    Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513CrossRefGoogle Scholar
  10. 10.
    Levy RA, de Jesus GR, de Jesus NR, Klumb EM (2016) Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 15(10):955–963CrossRefGoogle Scholar
  11. 11.
    Olesińska M, Wiesik-Szewczyk E, Chwalińska-Sadowska H (2007) Evaluation of systemic lupus erythematosus activity during pregnancy. Pol Arch Med Wewn 117(7):312–316PubMedGoogle Scholar
  12. 12.
    Clowse ME, Magder LS, Witter F, Petri M (2005) The impact of increased lupus activity on obstetric outcomes. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 52(2):514–521CrossRefGoogle Scholar
  13. 13.
    Nalli C, Iodice A, Andreoli L, Lojacono A, Motta M, Fazzi E, Tincani A (2014) The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus 23(6):507–517CrossRefGoogle Scholar
  14. 14.
    Doria A, Tincani A, Lockshin M (2008) Challenges of lupus pregnancies. Rheumatology 47(suppl_3):iii9–iii12PubMedGoogle Scholar
  15. 15.
    Clowse ME, Magder LS, Witter F, Petri M (2006) Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107(2):293–299CrossRefGoogle Scholar
  16. 16.
    Clowse ME, Magder LS, Petri M (2011) The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. The Journal of rheumatology:jrheum 100746Google Scholar
  17. 17.
    Yang M-J, Chen C-Y, Chang W-H, Tseng J-Y, Yeh C-C (2015) Pregnancy outcome of systemic lupus erythematosus in relation to lupus activity before and during pregnancy. Journal of the Chinese Medical Association 78(4):235–240CrossRefGoogle Scholar
  18. 18.
    Phansenee S, Sekararithi R, Jatavan P, Tongsong T (2018) Pregnancy outcomes among women with systemic lupus erythematosus: a retrospective cohort study from Thailand. Lupus 27(1):158–164CrossRefGoogle Scholar
  19. 19.
    Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon J-B, Dallay D, Pellegrin J, Boukerrou M, Blanco P, Lazaro E (2015) Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 24(13):1384–1391CrossRefGoogle Scholar
  20. 20.
    Reggia R, Bazzani C, Andreoli L, Motta M, Lojacono A, Zatti S, Ramazzotto F, Nuzzo M, Tincani A (2016) The efficacy and safety of cyclosporin A in pregnant patients with systemic autoimmune diseases. Am J Reprod Immunol 75(6):654–660CrossRefGoogle Scholar
  21. 21.
    Ponticelli C, Moroni G (2015) Immunosuppression in pregnant women with systemic lupus erythematosus. Taylor & Francis, Immunosuppression in pregnant women with systemic lupus erythematosus,Google Scholar
  22. 22.
    Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Centers NFP, Shechtman S, Johnson D, Cuppers-Maarschalkerweerd B, Pistelli A (2014) Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheum 66(5):1101–1110CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Golestan Hospital Clinical Research Development UnitAhvaz Jundishapur University of Medical SciencesAhvazIran
  2. 2.Department of Obstetrics and Gynecology, Fertility, Infertility and Perinatology Research Center, Faculty of MedicineAhvaz Jundishapour University of Medical SciencesAhvazIran
  3. 3.Thalassemia and Hemoglobinopathy Research Center, Research Institute of HealthAhvaz Jundishapur University of Medical SciencesAhvazIran
  4. 4.Department of Statistics and Epidemiology School of Public HealthAhvaz Jundishapur University of Medical SciencesAhvazIran

Personalised recommendations